Rose 95 Stock Portfolio March Madness Q1 Update Including Cost/Share And Purchase Evaluation ListSeeking Alpha • 04/13/21
Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney CancerBenzinga • 04/08/21
Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following SurgeryBusiness Wire • 04/08/21
IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma PatientsBenzinga • 04/07/21